VASO Corp (VASO) company profile
Close on Oct 19, 2026Market cap $51.17MP/E 29.0Yield –
About VASO
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Vaso Corporation operates in the healthcare equipment and information technology sectors through three business segments. Its IT segment provides managed network infrastructure, transport, and network security services. The professional sales service segment serves as an exclusive representative selling GE HealthCare diagnostic imaging equipment, ultrasound systems, service contracts, and training to healthcare providers in the middle market. Its medical equipment segment designs, manufactures, and services cardiovascular diagnostic and therapeutic products. These offerings include ambulatory blood pressure and ECG monitors, physiological analysis software, wireless vital-sign monitors, and external counterpulsation therapy systems.
Headquartered in Plainview, New York, the company operates additional facilities in Tampa, Florida, and Wuxi, China, employing 282 full-time personnel. Its commercial sales team covers 48 contiguous U.S. states, Alaska, and the District of Columbia, while its network services operate across all 50 states. Vaso maintains manufacturing in China and New York, distributing medical devices directly in the United States and China and through independent distributors across international markets.
Summary of the business section of VASO's latest annual report, written by StockData.
Company profile
Company
- Legal name
- VASO Corp
- Founded
- 1987
- Headquarters
- Plainview, NY
- Address
- 137 Commercial Street, Ste. 200 11803
- Phone
- (516) 997-4600
- Website
- vasocorporation.com
- Employees
- 282, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- UHY LLP, Sterling Heights, Michigan
Stock & identifiers
- Ticker
- VASO
- Exchange
- OTC
- IPO date
- Aug 18, 1995
- Shares outstanding
- 176M, Aug 12, 2026
- Public float
- $12.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 839087
- CUSIP
- 92233F102
- ISIN
- US92233F1021
- FIGI
- BBG000DP5SH4
- Share class FIGI
- BBG001S8HML9
- LEI
- 549300O0FA66XDLHTH45
- EIN
- 11-2871434
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jun Ma | Chief Exec Officer & President, Director | 10,498,146 |
| Shaun D. McMeans | Director | 100,000 |
| Leon Dembo | Director | 150,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $807.49K | $807.49K | $563.58K | $100 | – |
| FY2024 | $756.64K | $756.64K | $544.26K | $71 | – |
| FY2023 | $921.61K | $971.61K | $549.11K | $182 | – |
| FY2022 | $805.32K | $975.32K | $466.63K | $340 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Jun Ma, PhD Chief Executive Officer | $500.00K | $200.00K | $56.64K | $756.64K | -18% |
| Jane Moen President of Vasohealthcare, Chief Operating Officer | $350.00K | $300.00K | $61.38K | $711.38K | -2% |
| Peter C. Castle President of VasoTechnology | $350.00K | – | $12.00K | $362.00K | -18% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 282 full-time persons, of which 15 are employed through our headquarters and VasoMedical facility in Plainview, New York; 109 through VasoHealthcare; 102 through our NetWolves operations; and 56 in our China operations.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?